The Clinical Translational Research Award intends to support correlative studies that are associated with a clinical trial (past, ongoing, or future), in order to correlate various factors (genetic, biochemical, environmental and others) with initiation, progression, metastasis, recurrence, prognosis, diagnosis or effect of intervention on ovarian cancer outcomes. The translational research should address high-impact or unmet needs in ovarian cancer. Although not all-inclusive, research proposed under this mechanism may entail initiation of a deeper molecular analysis of clinical samples, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial. The proposed research may be hypothesis testing or may be designed to generate clinically annotated and molecularly characterized experimental platforms (e.g., tissue arrays, patient-derived models). The award may not be used to directly support a clinical trial.
Deadlines:
• Required Pre-Application Deadline: May 26, 2023
• Application Submission Deadline: July 21, 2023
To be considered for funding, applications for the FY23 OCRP Clinical Translational Research Award must address a critical component of at least one of the Areas of Emphasis listed below, unless adequate justification for exception is provided.* • Understand the basic biology and etiology of ovarian cancer initiation, progression, metastasis, recurrence, genetics, proteogenomic, and other critical events. • Develop novel therapeutic strategies for treatment and prevention. • Identify and develop new strategies for screening, early-stage detection, accurate diagnosis and prognosis. • Identify and implement strategies to improve survivorship and quality of life. • Address health disparities. • Improve precision medicine
The Principal Investigator (PI) must be at or above the level of Assistant Professor (or equivalent) to be eligible to submit an application. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.
The anticipated direct costs budgeted for the entire period of performance for an FY23 OCRP Clinical Translational Research Award should not exceed $2.0M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.